Novel therapeutic modalities and drug delivery – erlotinib liposomes modified with galactosylated lipid: in vitro and in vivo investigations

References

• International Agency for Research on Cancer, World Health Organization. 2012. GLOBOCAN 2012: Estimated cancer incidence, mortality and prevalence worldwide in 2012. Lyon, France: IARC, WHO.
   Google Scholar
• El-Serag HB. Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology. 2012;142:1264–1273.
   PubMed Web of Science ®Google Scholar
• Kim DY, Han KH. Epidemiology and surveillance of hepatocellular carcinoma. Liver Cancer. 2012;1:2–14.
   PubMed Web of Science ®Google Scholar
• Cheng JW, Lv Y. New progress of non-surgical treatments for hepatocellular carcinoma. Med Oncol. 2013;30:381.
   PubMed Web of Science ®Google Scholar
• Usmani A, Mishra A, Ahmad M. Nanomedicines: a theranostic approach for hepatocellular carcinoma. Artif Cells Nanomed Biotechnol. 2017;8:1–11.
   Google Scholar
• Von Pawel J. Gefitinib (Iressa, ZD1839): a novel targeted approach for the treatment of solid tumors. Bull Cancer. 2004;91:E70–E76.
   PubMedGoogle Scholar
• Zhong H, Bowen JP. Recent advances in small molecule inhibitors of VEGFR and EGFR signaling pathways. Curr Top Med Chem. 2011;11:1571–1590.
   PubMed Web of Science ®Google Scholar
• Clay D, Lipman YM, Bonk ME. Erlotinib (Tarceva®): a brief overview. P and T. 2005;30:561–602.
   Google Scholar
• Smith J. Erlotinib: small-molecule targeted therapy in the treatment of non-small-cell lung cancer. Clin Ther. 2005;27:1513–1534.
   PubMed Web of Science ®Google Scholar
• Makrilia N, Lappa T, Xyla V, et al. The role of angiogenesis in solid tumours: an overview. Eur J Intern Med. 2009;20:663–671.
   PubMed Web of Science ®Google Scholar
• Philip PA, Mahoney MR, Allmer C, et al. Phase II study of erlotinib (OSI-774) in patients with advanced hepatocellular cancer. J Clin Oncol. 2005;23:6657–6663.
   PubMed Web of Science ®Google Scholar
• Thomas MB, Chadha R, Glover K, et al. Phase 2 study of erlotinib in patients with unresectable hepatocellular carcinoma. Cancer. 2007;110:1059–1067.
   PubMed Web of Science ®Google Scholar
• Thomas MB, Morris JS, Chadha R, et al. Phase II trial of the combination of bevacizumab and erlotinib in patients who have advanced hepatocellular carcinoma. J Clin Oncol. 2009;27:843–850.
   PubMed Web of Science ®Google Scholar
• Kaseb AO, Garrett-Mayer E, Morris JS, et al. Efficacy of bevacizumab plus erlotinib for advanced hepatocellular carcinoma and predictors of outcome: final results of a phase II trial. Oncology. 2012;82:67–74.
   PubMed Web of Science ®Google Scholar
• Philip PA, Mahoney MR, Holen KD, et al. Phase 2 study of bevacizumab plus erlotinib in patients with advanced hepatocellular cancer. Cancer. 2012;118:2424–2430.
   PubMed Web of Science ®Google Scholar
• Swaisland HC, Smith RP, Laight A, et al. Single-dose clinical pharmacokinetic studies of gefitinib. Clin Pharmacokinet. 2005;44:1165–1177.
   PubMed Web of Science ®Google Scholar
• Ranson M, Shaw H, Wolf J, et al. A phase I dose-escalation and bioavailability study of oral and intravenous formulations of erlotinib (Tarceva, OSI-774) in patients with advanced solid tumors of epithelial origin. Cancer Chemother Pharmacol. 2010;66:53–58.
   PubMed Web of Science ®Google Scholar
• Momin MM, Zaheer Z, Zainuddin R, et al. Extended release delivery of erlotinib glutathione nanosponge for targeting lung cancer. Artif Cells Nanomed Biotechnol. 2017;31:1–12.
   Google Scholar
• Vrignaud S, Hureaux J, Wack S, et al. Design, optimization and in vitro evaluation of reverse micelle-loaded lipid nanocarriers containing erlotinib hydrochloride. Int J Pharm. 2012;436:194–200.
   PubMed Web of Science ®Google Scholar
• Xu Y, Karmakar A, Heberlein WE, et al. Multifunctional magnetic nanoparticles for synergistic enhancement of cancer treatment by combinatorial radio frequency thermolysis and drug delivery. Adv Healthcare Mater. 2012;1:493–501.
   Web of Science ®Google Scholar
• Kelly C, Jefferies C, Cryan SA. Targeted liposomal drug delivery to monocytes and macrophages. J Drug Deliv. 2011;2011:727241.
   PubMedGoogle Scholar
• Bardania H, Tarvirdipour S, Dorkoosh F. Liposome-targeted delivery for highly potent drugs. Artif Cells Nanomed Biotechnol. 2017;17:1–12.
   Google Scholar
• Ashwell G, Harford J. Carbohydrate-specific receptors of the liver. Annu Rev Biochem. 1982;51:531–554.
   PubMed Web of Science ®Google Scholar
• Wu J, Nantz MH, Zern MA. Targeting hepatocytes for drug and gene delivery: emerging novel approaches and applications. Front Biosci. 2002;7:d717–d725.
   PubMed Web of Science ®Google Scholar
• Eliaz RE, Szoka FC Jr, Liposome-encapsulated doxorubicin targeted to CD44: a strategy to kill CD44-overexpressing tumor cells. Cancer Res. 2001;61:2592–2601.
   PubMed Web of Science ®Google Scholar
• Lasic DD, Frederik PM, Stuart MC, et al. Gelation of liposome interior. A novel method for drug encapsulation. FEBS Lett. 1992;312:255–258.
   PubMed Web of Science ®Google Scholar
• Bolandnazar S, Divsalar A, Valizadeh H, et al. Development and application of an HPLC method for erlotinib protein binding studies. Adv Pharm Bull. 2013;3:289–293.
   PubMedGoogle Scholar
• Lankheet NA, Hillebrand MJ, Rosing H, et al. Method development and validation for the quantification of dasatinib, erlotinib, gefitinib, imatinib, lapatinib, nilotinib, sorafenib and sunitinib in human plasma by liquid chromatography coupled with tandem mass spectrometry. Biomed Chromatogr. 2013;27:466–476.
   PubMed Web of Science ®Google Scholar